


PHARMACEUTICAL 2019



Calithera Biosciences Inc. Rank 150 of 371



RealRate

PHARMACEUTICAL 2019



Calithera Biosciences Inc. Rank 150 of 371

The relative strengths and weaknesses of Calithera Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Calithera Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 145% points. The greatest weakness of Calithera Biosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 162% points.

The company's Economic Capital Ratio, given in the ranking table, is -103%, being 228% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	140,252
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,881
Liabilities, Non-Current	0
Other Assets	1,009
Other Compr. Net Income	157
Other Expenses	0
Other Liabilities	1,130
Other Net Income	2,652
Property and Equipment	1,464
Research and Development	66,195
Revenues	22,254
Selling, General and Administrative Expense	13,340

Output Variable	Value in 1000 USD
Assets	142,725
Liabilities	16,011
Expenses	79,535
Stockholders Equity	126,714
Net Income	-54,629
Comprehensive Net Income	-54,550
Economic Capital Ratio	-103%